Regulatory Challenges in the CIS and Russia - TOPRA In CEE WebinarNovember 22, 2023
Inpharmatis opened an official representative office in Tashkent
The office in Uzbekistan will become the regional “hub” of Inpharmatis in Central Asia, noted the company`s CEO Dr. Polina Dombure.
“The pharmaceutical industry of Uzbekistan is developing dynamically, manufacturers are actively introducing innovative solutions both in the production and registration of medicines. Today, enterprises of the world's leading pharmaceutical manufacturers are represented in Uzbekistan, medicines are in demand not only in the domestic market but are also actively exported abroad. The representative office of Inpharmatis in Uzbekistan will become a regional “hub” for Central Asia. We are confident that more than 15 years of experience of Inpharmatis in the countries of the European Union and the CIS will allow our company to make a significant contribution to the development of pharmaceutical production in Uzbekistan,” said Polina Dombure.
Saidamir Sadikov, Head of the Inpharmatis representative office in Tashkent, said that: “The opening of an official representative office in Uzbekistan provides new opportunities for cooperation of Inpharmatis both with state regulatory bodies of the Republic of Uzbekistan and with pharmaceutical manufacturers”.
Inpharmatis considers the most promising areas for a partnership to be the automation of quality management in pharmaceutical production, electronic solutions for regulating access to the pharmaceutical market, GMP audits, and joint projects in the field of Regulatory Affairs and pharmacovigilance.
According to the Ministry of Foreign Trade of Uzbekistan, today there are 152 pharmaceutical enterprises in the country that produce 2,373 names of medicines. There are 8 research institutes and centers. In addition, the only plant in Central Asia is located in Uzbekistan, which specializes in the production of insulin used for the treatment of diabetes mellitus.
Особенности выбора типа Пользовательского тестирования листка-вкладыша в ЕАЭСNovember 01, 2023
Features of Choosing the Type of PIL RUT in EAEUNovember 01, 2023
PIL Readability User Testing in EAEU Special Autumn OfferOctober 25, 2023
Специальное Осеннее Предложение по пользовательскому тестированию листка-вкладышаOctober 24, 2023
PIL Readability Testing is Mandatory in EAEUFebruary 15, 2022
Пользовательское тестирование по ЕАЭС – обязательная процедураFebruary 14, 2022
One More Inpharmatis Team Member Gets PhD in Pharmaceutical SciencesJanuary 27, 2022
В штате Inpharmatis стало на одного доктора фармацевтических наук большеJanuary 27, 2022
Pharma 4.0: Data-Driven RegulationJanuary 18, 2022